Loading...
•
Mar 31, 2023
OPKO Health Q1 2023 Earnings Report
Reported business highlights and financial results for Q1 2023.
Key Takeaways
OPKO Health reported a decrease in consolidated total revenues to $237.6 million compared to $329.2 million for the same period in 2022. The operating loss decreased to $30.6 million from $72.4 million in the previous year, and the net loss was $18.3 million, or $0.02 per share, compared to a net loss of $55.4 million, or $0.08 per share, for the 2022 quarter.
ModeX Therapeutics entered into an exclusive worldwide license and collaboration agreement with Merck for MDX-2201, receiving a $50.0 million upfront payment.
Pfizer is actively selling NGENLA® in 17 countries, with approvals in 41 countries, while awaiting FDA approval in the U.S.
BioReference Health is offering a dual-stain triage test to enhance cervical cancer screenings.
Revenue from products increased to $40.4 million, driven by international sales and Rayaldee sales.
Forward Guidance
OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...